Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Novo Nordisk said it had been able to ease some of the restrictions ... Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy ...

So even a billion-dollar-or-so swing in Zepbound's future sales ... Additionally, Lilly could leverage specialty pharmacies or direct-to-patient models to bypass some PBM restrictions.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Eli Lilly is working on a new drug, orforglipron, an oral tablet taken once daily, with no dietary restrictions ... Eli Lilly's total sales between Mounjaro and Zepbound were slightly under ...